<DOC>
	<DOC>NCT01208831</DOC>
	<brief_summary>The purpose of this study is to determine Maximum Tolerated Dose (MTD) or recommended phase II dose of LDE225 when administered orally to two adult patient groups of East Asian (i.e., Japanese and Chinese/Taiwanese) with advanced solid tumors that have progressed despite standard therapy or for which no standard therapy exists.</brief_summary>
	<brief_title>An East Asian Study of LDE225</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Basal Cell</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<criteria>confirmed diagnosis of advanced solid tumor (including medulloblastoma and basal cell carcinoma) blood work criteria patients with history of brain tumor (except recurrent medulloblastoma) or brain metastases positive HIV, hepatitis B or C impaired intestinal function impaired heart function pregnant or breastfeeding women Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Advanced tumors</keyword>
	<keyword>hedgehog</keyword>
	<keyword>smoothened inhibitor</keyword>
</DOC>